Neoadjuvant tamoxifen and aromatase inhibitors: Comparisons and clinical outcomes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 295-299

  Dixon, J M ^a   Jackson, J ^a   Renshaw, L ^a   Miller, W R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; ER and or PgR positive; Neoadjuvant tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; MULTICENTER STUDY; POSTMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0242541296     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00370-4     Document Type: Conference Paper

References (30)

1. Bear H. Indications for neoadjuvant therapy for breast cancer. Semin. Oncol. 25(Suppl. 3):1998;3-12.
2. Perloff M., Lesnick G.J. Chemotherapy before and after mastectomy in stage III breast cancer. Arch. Surg. 117:1982;879-881.
3. Schick P., Goodstein J., Moor J., Butler J., Senter K.L. Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J. Surg. Oncol. 22:1983;278-282.
4. Bonadonna G., Veronesi U., Brambilla C.et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of 3 cm or more. J. Natl. Cancer Inst. 82:1990;1539-1545.
5. Ellis M.J., Coop A., Singh B.et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, oestrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19:2001;3808-3816.
6. Mustacchi G., Milani S., Pluchinotta A., De Matteis A., Rubagott A., Perrota A. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer. GRETA Trial Anticancer Res. 14:1994;2197-2200.
7. Gazet J.C., Ford H.T., Coombes R.C., Bland J.M., Sutcliffe R., Quilliam J., Lowndes S. Prospective ramdomised trial of tamoxifen vs. surgery in elderly patients with breast cancer. Eur. J. Surg. Oncol. 20:1994;207-214.
8. Van Dalsen A.D., De Vries J. Treatment of breast cancer in elderly patients. J. Surg. Oncol. 60:1995;80-82.
9. Bates T., Riley D.L., Houghton J., Fallowfield L., Baum M. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br. J. Surg. 78:1991;591-594.
10. Kenny F.S., Robertson J.F.R., Ellis I.O., Elston C.W., Blamey R.W. Primary tamoxifen versus mastectomy and adjuvant tamoxifen in fit elderly patient with operable breast cancer of high ER content. Breast. 8:1999;216.
11. J.M. Dixon, Neoadjuvant Endocrine Therapy. Breast Cancer Diagnosis and Management, Elsevier, London, 2000 (Chapter 38).
12. Dixon J.M., Love C.D.B., Bellamy C.O.C., Cameron D.A., Leonard R.C.F., Smith H., Miller W.R. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res. Treat. 66(3):2001;191-199.
13. Eiermann W., Paepke S., Appfelstaedt J.et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12:2001;1527-1532.
14. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., Miller W.R. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res. 6:2000;2229-2235.
15. J.M. Dixon, J. Jackson, M. Hills, L. Renshaw, D.A. Cameron, T.J. Anderson, W.R. Miller, M. Dowsett, Anastrozole demonstrates clinical and biological effectiveness in erbB2 ER positive breast cancers, Breast Cancer Res Treat., in press.
16. J.M. Dixon, J. Jackson, L. Renshaw, D.A. Cameron, W.R. Miller, Neoadjuvant letrozole: the Edinburgh experience, Breast Cancer Res. Treat., in press.
17. Goldie J.H. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin. Oncol. 14:1987;1.
18. J.M. Dixon, Neoadjuvant therapy: surgical perspectives, in: W.R. Miller, J.N. Ingle (Eds.), Endocrine Therapy in Breast Cancer, Marcel Dekker, New York, 2002, pp. 197-212.
19. Bonadonna G., Valagussa P., Brambilla C.et al. Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin. Oncol. 15:1991;515-524.
20. Veronesi U., Bonadonna G., Zurrida S.et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann. Surg. 222:1995;612-618.
21. Mauriac L., MacGrogan G., Avril A.et al. on behalf of Institute Bergonie Bordeaux Groupe Sein (IBBGS). Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomised trial with a 124-month follow up. Ann. Oncol. 10:1990;47-52.
22. Moneer M., El-Didi M., Khaled H. Breast conservation surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy - a pathological assessment. The Breast. 8:1999;315-319.
23. J.M. Dixon, T.J. Anderson, W.R. Miller, Neoadjuvant endocrine therapy of breast cancer: a surgical perspective, Eur. J. Cancer, in press.
24. Veronesi U., Bonadonna G., Zurrida S., Andreola S., Rilke F., Raselli R., Merson M., Sacchini V., Agresti R. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann. Surg. 222:1995;612-618.
25. Makris A., Powles T.J., Ashley S.E.et al. A reduction in the requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann. Oncol. 9:1998;1179-1184.
26. Kurtz J.M. Should surgery remain the initial treatment of operable breast cancer? Eur. J. Cancer. 27(12):1991;1539-1542.
27. Fisher B., Bryant J., Womark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz A.B. Jr., Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8):1998;2672-2678.
28. Mauriac L., Durand M., Avril A., Dilhuydy J.M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Results of a randomised trial in a single centre. Ann. Oncol. 2(5):1991;347-354.
29. Semiglazov V.F., Topuzov E.E., Bavli J.L., Moiseyendo V.M., Ivanova O.A., Seleznev I.K., Orlov A.A., Barash N.Y., Golubeva O.M., Chepic O.F. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann. Oncol. 5(7):1994;591-595.
30. Cameron D.A., Jack W., Forouhi P., Keen J., Dixon J.M., Leonard R.C.F., Chetty U. Oestrogen receptor directed primary systemic therapy: a randomised trial compared with conventional therapy in operable breast cancer. Breast Cancer Res. Treat. 76(Suppl.):2002;S5. Abstract 157.